9 recruiting, 9 unknown, 8 active not recruiting, 5 completed. 12 Phase 2, 11 Phase 1, 4 Phase 3, 2 Early Phase 1.
Follow Neuroendocrine Neoplasm: new trials by email Literature Review of Neuroendocrine Neoplasm trials Research Report on Neuroendocrine Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms Somatostatin Analogue(s) - Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm | Phase 3 | Not yet recruiting | Washington University School of Medicine | 240 | 2026-11-30 | 2026-10-19 |
| A Phase 1 Study of IM-1340 in Participants With Advanced Cancer IM-1340 - Colorectal Cancer, Non-Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Immunome, Inc. | 200 | 2026-11-01 | 2026-10-22 |
| Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms CTX-471 - Neuroendocrine Neoplasm, Neuroendocrine Carcinomas | Phase 2 | Not yet recruiting | Compass Therapeutics | 58 | 2026-09-01 | 2026-07-06 |
| A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors CRN09682 - SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors | Phase 1 / Phase 2 | Active not recruiting | Crinetics Pharmaceuticals Inc. | 150 | 2025-11-26 | 2026-10-13 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine Neoplasms Mixed Neuroendocrine-Non Neuroendocrine Neoplasm, Neuroendocrine Neoplasm | Recruiting | European Institute of Oncology | 130 | 2024-10-21 | 2025-01-21 | |
| A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens [225Ac]Ac-DOTATATE - Neuroendocrine Neoplasm | Phase 1 | Recruiting | Peking University Cancer Hospital & Institute | 36 | 2024-09-29 | 2025-06-26 |
| Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial Somatostatin analog - Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1 | Phase 2 / Phase 3 | Recruiting | The Netherlands Cancer Institute | 39 | 2024-06-25 | 2025-03-03 |
| Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors Neuroendocrine Neoplasm, China | Unknown | Fujian Maternity and Child Health Hospital | 300 | 2024-02-01 | 2024-09-19 | |
| A Study of PM8002 in Combination With Chemotherapy in Patients With NEN PM8002, FOLFIRI - Neuroendocrine Neoplasm | Phase 2 | Active not recruiting | Biotheus Inc. | 31 | 2023-05-17 | 2026-07-09 |
| YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs. Neuroendocrine Neoplasm, Adenocarcinoma | Recruiting | European Institute of Oncology | 90 | 2023-03-10 | 2024-03-29 | |
| Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract | Recruiting | Universidad Nacional Autonoma de Mexico | 750 | 2022-08-03 | 2024-07-26 | |
| Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE) Sintilimab, IBI310, Surufatinib - Neuroendocrine Neoplasm | Phase 2 | Recruiting | Peking University | 30 | 2022-07-12 | 2025-03-14 |
| Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm Chidamide, Sintilimab - Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3 | Phase 2 | Unknown | Peking Union Medical College Hospital | 23 | 2021-11-17 | 2021-11-24 |
| Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate - Neuroendocrine Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-07-22 | 2026-06-15 |
| Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients Neuroendocrine Neoplasm | Unknown | European Institute of Oncology | 20 | 2021-07-19 | 2024-05-06 | |
| Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis Biopsy/surgical tissue and peripheral blood - Neuroendocrine Neoplasm | Unknown | Xian-Jun Yu | 200 | 2021-07-01 | 2021-06-18 | |
| Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm Biopsy, open or laparoscopic surgery - Neuroendocrine Neoplasm | Unknown | Fudan University | 200 | 2021-06-06 | 2021-09-24 | |
| Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET) Bone Metastases, Neuroendocrine Neoplasm | Unknown | European Institute of Oncology | 500 | 2021-01-08 | 2021-01-22 | |
| Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) Somatostatin analog; chemotherapy - Neuroendocrine Tumors, Neuroendocrine Neoplasm | Recruiting | University of Roma La Sapienza | 60 | 2020-09-14 | 2025-04-03 |
Showing 20 of 36. Sign in to see all of them.
Neuroendocrine Tumors (36) · Carcinoma, Neuroendocrine (6) · Multiple Endocrine Neoplasia Type 1 (4) · Carcinoid Tumor (3) · Carcinoma, Medullary (3) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Pheochromocytoma (3) · Thyroid Neoplasms (3) · Urinary Bladder Neoplasms (3) · Uterine Cervical Neoplasms (3) · Adenoma, Islet Cell (2) · Adrenal Gland Neoplasms (2) · Brain Neoplasms (2) · Breast Neoplasms (2)
Neoplasms by Histologic Type (36) · Neoplasms, Germ Cell and Embryonal (36) · Neoplasms, Nerve Tissue (36) · Neuroectodermal Tumors (36) · Neoplasms (35) · Neoplasms, Glandular and Epithelial (16) · Carcinoma (15) · Neoplasms by Site (13) · Adenocarcinoma (12) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Thoracic Neoplasms (7) · Female Urogenital Diseases (5)
Magnetic Resonance Spectroscopy (5) · lutetium Lu 177 dotatate (3) · Biopsy (2) · Carboplatin (2) · Etoposide (2) · FAPI-46 (2) · Fluorodeoxyglucose F18 (2) · Somatostatin (2) · Specimen Handling (2) · pembrolizumab (2) · sintilimab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Acetates (1) · Al18F-NOTA-octreotide (1) · Bevacizumab (1)
European Institute of Oncology (4) · National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (3) · Jonsson Comprehensive Cancer Center (2) · Peking Union Medical College Hospital (2) · Biotheus Inc. (1) · Children's Oncology Group (1) · Compass Therapeutics (1) · Crinetics Pharmaceuticals Inc. (1) · Fudan University (1) · Fujian Maternity and Child Health Hospital (1) · Grupo Espanol de Tumores Neuroendocrinos (1) · Guangdong Zhongsheng Pharmaceutical Co., Ltd. (1) · Immunome, Inc. (1) · Nicholas Fidelman, MD (1)
United States (14) · China (10) · Italy (5) · Canada (2) · Spain (2) · Australia (1) · Denmark (1) · Mexico (1) · Netherlands (1) · New Zealand (1) · Puerto Rico (1) · Saudi Arabia (1)
Francesca Spada, MD (2) · Jeremie Calais (2) · Xianjun Yu, MD, PhD (2) · Andrea M Isidori, MD, PhD (1) · Chunmei Bai, M.D. (1) · Douglas S Hawkins (1) · Francesca Spada, M.D., Ph.D. (1) · Homer A Macapinlac, MD (1) · James C Yao (1) · James Welsh (1) · Jennifer A Chan (1) · Jianming Xu (1) · Jordan Berlin, M.D. (1) · Lowell B Anthony (1)
PMID 20150268, PMID 28384065, PMID 29295881, PMID 30893350, PMID 31605794, PMID 33152282, PMID 35205614, PMID 35657429, PMID 38581469, PMID 39117670, PMID 39282913, PMID 39863139, PMID 41524552
P30CA016672 (1), U01CA062505 (1), U01CA069912 (1), U01CA070095 (1), U01CA132123 (1), U10CA032102 (1), U10CA098543 (1), U10CA180821 (1), U10CA180888 (1), UM1CA186644 (1), UM1CA186686 (1), UM1CA186689 (1), UM1CA186690 (1), UM1CA186691 (1), UM1CA186712 (1)